ARTICLE | Company News
Almirall, Aslan deal
May 28, 2012 7:00 AM UTC
Almirall granted Aslan exclusive, worldwide rights to develop LAS186323, a dihydroorotate dehydrogenase (DHODH) inhibitor in Phase I testing for rheumatoid arthritis. Aslan will conduct and fund development through the end of Phase II trials, after which Aslan will find a partner for Phase III development and commercialization. Details were not disclosed. ...